How Record Revenues and a New Buyback Program Could Shape United Therapeutics' (UTHR) Long-Term Narrative

• United Therapeutics Corporation recently reported second-quarter 2025 financial results, highlighting record revenues of US$798.6 million and growth in both net income and earnings per share compared to the previous year. The company also authorized a US$1 billion share repurchase program and completed a shelf registration for 950,000 shares, signaling ongoing capital markets activity and confidence in future opportunities.
• Analysts are closely watching the company’s strong momentum in treprostinil-based therapies and upcoming clinical trial milestones, which could further expand its addressable markets and support future earnings potential.
• We’ll examine how the new US$1 billion share repurchase program could enhance United Therapeutics’ investment narrative and long-term outlook.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 25 companies in the world exploring or producing it. Find the list for free.

United Therapeutics Investment Narrative Recap

To be a shareholder in United Therapeutics, you need to believe in the company’s ability to maintain growth through both its flagship treprostinil products and a robust late-stage pipeline. The recent record revenue and $1 billion share repurchase add financial strength, but the most important short-term catalyst remains clinical data readouts, particularly from the TETON 2 study. These announcements do not materially alter near-term pipeline risks, especially the uncertainty of clinical trial outcomes.

Among recent announcements, United Therapeutics’ completion of enrollment for the Phase 3 ADVANCE OUTCOMES study is particularly relevant. This milestone sets the stage for key data in late 2025 and early 2026, which could influence future product approvals and market expansion for pulmonary arterial hypertension therapies.

On the other hand, investors should be mindful of the heightened risk if late-stage trials underperform expectations...

Read the full narrative on United Therapeutics (it's free!)

United Therapeutics' outlook calls for $3.6 billion in revenue and $1.5 billion in earnings by 2028. This is based on analysts forecasting 6.8% annual revenue growth and a $300 million increase in earnings from the current $1.2 billion.

Uncover how United Therapeutics' forecasts yield a $380.98 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community estimate United Therapeutics’ fair value between US$227.09 and US$945.61 per share. While opinions differ widely, clinical trial risks remain a key focus for the company’s outlook.

Explore 4 other fair value estimates on United Therapeutics - why the stock might be worth over 3x more than the current price!

Build Your Own United Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your United Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com